HK Stock Market Move | LAIFUAL (03952) surged over 6% in the afternoon. Domestic Siasun Robot & Automation's main factory is ramping up production, which is expected to drive a significant increase in component orders.
Lai Fu Harmonics (03952) rose over 6% in the afternoon, and as of the time of publication, it was up 5.89%, priced at HKD 68.35, with a transaction volume of HKD 9.7476 million.
LAIFUAL (03952) surged over 6% in the afternoon, and as of the time of writing, it rose 5.89% to HKD 68.35, with a trading volume of HKD 9.7476 million.
In terms of news, the domestic Siasun Robot & Automation core factory is ramping up production. Huafu Securities pointed out that domestic component companies supporting the core factory may face a conflict between capacity shortages and expansion cycles, similar to the previous trajectory of the optical module industry chain. This could lead to a mismatch in supply and demand, with orders expected to continue increasing significantly. Whole machine manufacturers and related component suppliers are likely to benefit first from this production ramp-up cycle.
According to the prospectus, LAIFUAL is a key provider of precision drive components for Siasun Robot & Automation in China. According to the Zhizhi Consulting report, by 2025, LAIFUAL ranks second among Siasun Robot & Automation's harmonic reducer suppliers in China based on shipment volume, with a market share of 21.4%. In terms of revenue, it also ranks second, with a market share of 12.9%. By the end of 2025, LAIFUAL will be one of the only two manufacturers in the country that have successfully delivered humanoid Siasun Robot & Automation harmonic reducers and entered the mass production stage.
Related Articles

Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary has obtained the drug registration certificate for Tranexamic Acid and Sodium Chloride Injection.

DRAM and NAND shipments surged by over 370%! Wells Fargo states that the rising costs of AI infrastructure are not a red flag, and the semiconductor boom cycle continues.

Sanofi (SNY.US) submits a new indication for its long-acting RSV monoclonal antibody for market approval.
Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary has obtained the drug registration certificate for Tranexamic Acid and Sodium Chloride Injection.

DRAM and NAND shipments surged by over 370%! Wells Fargo states that the rising costs of AI infrastructure are not a red flag, and the semiconductor boom cycle continues.

Sanofi (SNY.US) submits a new indication for its long-acting RSV monoclonal antibody for market approval.

RECOMMEND





